One Exchange Square
8 Connaught Place
Central, Hong Kong
Our Asia practice, based in Hong Kong, includes lawyers who are qualified to practice law in Hong Kong, England & Wales, the U.S., Canada, India, the People's Republic of China and Taiwan, who are able to speak a range of languages including English, Mandarin, Cantonese, Hindi and Taiwanese.
Our comprehensive Asia practice is focused on Capital Markets, Corporate, Mergers + Acquisitions, Debt Finance, Private Equity, Private Investment Funds, Venture Capital, Life Sciences, Real Estate and TMT (Technology, Media & Telecom) sectors.
We have been named Top Law Firm in Private Equity & Venture Capital by China Business Law Journal in 2017-2018, a Leading International Firm for India-related work by India Business Law Journal since 2008, and a Leading Law Firm for Corporate/M&A (International Firms) in India by Chambers Asia Pacific for many years including recently in 2018.
MARKET-LEADING TMT PRACTICE
We have built a market-leading technology, media and telecom (TMT) practice that covers a broad range of corporate transactions. Our notable strength is in private equity and growth equity, pooled investments and funds, international capital-raising and exchange listing activities, cross-border M&A, as well as joint ventures and restructurings. Our lawyers have worked with leading technology investors and companies. These include transactions involving AbsolutData, Alibaba Group, BillDesk, Canyon Bridge, Crystal Stream, Didi Chuxing, DST Global, Falcon Edge Capital, Flipkart, FountainVest Partners, Fractal Analytics, Go Jek, Hillhouse Capital, Horizons Ventures, IMAX, JD.com, Koudai, Meituan, Micromax, Olacabs, Quilvest, RRE Ventures, Snapdeal, Tencent, Vy Capital, Xiaomi, Zodius/Advendus Capital, and Zomato.
LIFE SCIENCES EXPERTISE
Goodwin’s team of highly experienced lawyers resident in key life sciences hubs including in Asia helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle. From capital markets and IPOs, mergers and acquisitions, collaborations and licensing, royalty monetization, strategic guidance, intellectual property, and regulatory, our fully integrated team is built to serve all legal needs for global life sciences companies. Our recent Asia experience includes advising on the Hong Kong IPOs of AOBiome and Ascentage, and BeiGene’s US IPO, as well as leading Asia-based private equity funds on their investments in the life sciences sector.